Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Net Margin (2018 - 2025)

Lipocine's Net Margin history spans 8 years, with the latest figure at 2781.46% for Q3 2025.

  • For Q3 2025, Net Margin changed N/A year-over-year to 2781.46%; the TTM value through Sep 2025 reached 126.75%, down 7188.0%, while the annual FY2024 figure was 0.08%, 57352.0% up from the prior year.
  • Net Margin reached 2781.46% in Q3 2025 per LPCN's latest filing, down from 354.13% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 11856.66% in Q2 2021 to a low of 7038.22% in Q1 2023.
  • Average Net Margin over 5 years is 275.94%, with a median of 283.58% recorded in 2023.
  • Peak YoY movement for Net Margin: crashed -1238301bps in 2022, then surged 708435bps in 2024.
  • A 5-year view of Net Margin shows it stood at 78.48% in 2021, then plummeted by -771bps to 526.36% in 2022, then soared by 301bps to 1055.68% in 2023, then crashed by -95bps to 50.94% in 2024, then crashed by -5560bps to 2781.46% in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Net Margin are 2781.46% (Q3 2025), 354.13% (Q2 2025), and 1986.78% (Q1 2025).